Advertisement

Topics

XBIOTECH Company Profile

13:27 EST 13th December 2018 | BioPortfolio

Nil

Contact

Phone: 41(0)44 789 98 46
Email: info@xbiotech.ch


News Articles [36 Associated News Articles listed on BioPortfolio]

XBiotech Inc.: XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases

Broad European Patent Issued Supports XBiotech's Skin Disease Program for Monoclonal Antibody BermekimabAUSTIN, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced toda...

XBiotech Inc.: XBiotech Highlights Quarterly Developments

Company Provides Updated Overview on its Clinical, Discovery and Financial PositionAUSTIN, Texas, Aug. 10, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) provided an update on recent corpora...

XBiotech Inc.: XBiotech Highlights Third Quarter Developments for 2018

Company Provides Updated Overview including on its Clinical and Discovery Pipeline as well as Other Corporate Initiatives AUSTIN, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBI...

XBiotech Inc.: XBiotech berichtet über Entwicklungen im dritten Quartal 2018

Unternehmen stellt aktualisierte Übersicht zur klinischen und Entdeckungs-Pipeline sowie anderen Unternehmensinitiativen vor AUSTIN, Texas, Nov. 02, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: .....

XBiotech Inc.: XBiotech Announces Successful Completion of GMP Audit

First Audit in Company's New Manufacturing Facility Shows Compliance with GMP GuidelinesAUSTIN, Texas, Dec. 03, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced a successful GMP...

XBiotech Inc.: XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks

Findings Demonstrate Ability of MABp1 (Bermekimab) to Block In Vitro Neutrophil Mediated Vascular Endothelial Activation and ThrombosisAUSTIN, Texas, Aug. 27, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc....

XBiotech Inc.: XBiotech gibt Zugang des weltweit führenden Kardiologen Dr. Peter Libby zu seinem wissenschaftlichen Beirat bekannt

AUSTIN, Texas, Sept. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) freut sich, die Ernennung von Dr. Peter Libby zum Mitglied des wissenschaftlichen Beirats (SAB) des Unternehmens bekan...

XBiotech Inc.: XBiotech gibt den Abschluss der Rekrutierungsphase einer multizentrischen Studie der Phase II zur Beurteilung von Bermekimab bei Patienten mit atopischer Dermatitis bekannt

AUSTIN, Texas, Oct. 05, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) hat heute bekanntgegeben, dass das Unternehmen die Rekrutierungsphase seiner offenen klinischen Studie der Phase II zur...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

More Information about "XBIOTECH" on BioPortfolio

We have published hundreds of XBIOTECH news stories on BioPortfolio along with dozens of XBIOTECH Clinical Trials and PubMed Articles about XBIOTECH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of XBIOTECH Companies in our database. You can also find out about relevant XBIOTECH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record